Centrex Announces Investment by Future CEO.

Business Editors

TULSA, Okla.--(BUSINESS WIRE)--April 16, 2003

Centrex, Inc. (OTCBB:CNEX) today announced that Jack J. Luchese has made a personal investment of $250,000 to Centrex, Inc. comprised of approximately $100,000 in cash and approximately $150,000 in fee waivers. Mr. Luchese is currently committed to the Company as a full time consultant, and will assume his role as CEO and Director once the initial round of $2 million in funding has been completed. He will replace Dr. Thomas R. Coughlin, Jr., the current CEO, who will remain with the Company as a Technical Advisor.

According to Dr. Coughlin, Centrex's current CEO, the funds will be used for ongoing research and for company operations. "We at Centrex feel that biodefense and Homeland Security issues are everyone's responsibility. Jack has chosen to take the lead in attempting to accelerate the development of our advanced biodetection technology into products that will become powerful detection tools against terrorism. What once seemed unimaginable now seems inevitable and thorough preparation is our only defense against a future bioterrorism attack. Centrex is currently developing a system designed to provide rapid, automated and accurate detection of biological agents that might be used in a terrorist attack, but also has potential in other areas of biodetection. The possible applications for the Centrex technology include not only bioterrorism and Homeland Security, but also food and water processing, blood supply screening, and general DNA testing. The utilization of the technology outside of the Homeland Security arena provides additional outstanding market opportunities for Centrex."

Centrex, Inc. is a development stage company that owns the exclusive worldwide license to develop, manufacture and market a system for detecting microbial contamination in air, food and water. The detection system is designed to be adaptable and easily tailored to detect a variety of bacterial or viral organisms by recognizing the unique DNA fingerprint of the organism. The proposed device is a simultaneous multi-channel detection system that is compact, fully automated and capable of monitoring the presence of biological agents in air, food and water.

For more information, visit the Centrex Web site at www.centrexcorporation.com.

This press release contains some forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are discussed in the Company's SEC filings.